论文部分内容阅读
嵌合抗原受体T细胞(CAR-T)疗法是近年来兴起的一种肿瘤免疫治疗策略，尤以在弥漫性大B细胞淋巴瘤和急性淋巴细胞白血病中疗效最佳，但受限于实体瘤复杂的肿瘤微环境，CAR-T疗法在实体瘤治疗中的应用仍处于研究阶段。分子影像能够实时、深度、有效地对T细胞的体内状态进行示踪，对考察CAR-T在体内的生物学行为、评价CAR-T的激活状态具有重要意义。此外，分子影像还可对CAR-T治疗效果及可能产生的相关不良反应进行早期预测，从而为临床干预提供有效信息，并在指导CAR-T疗法研发中起到重要作用。“,”Chimeric antigen receptor T-cell (CAR-T) therapy is an emerging cancer immunotherapy strategy in recent years. CAR-T therapy has shown significant efficacy in the treatment of relapsed or refractory diffuse large B cell lymphoma and refractory pediatric acute lymphoblastic leukemia. However, restricted by the complexity of solid tumor microenvironment, the application of CAR-T therapy in solid tumors is still underway. Molecular imaging can trace the n in vivo status of T cells in real time and in depth, which is of great significance to investigate the biological behavior of CAR-T cells n in vivo and to evaluate their activation status. Meanwhile, molecular imaging strategy can also act as an early predictor of CAR-T treatment efficacy and related side effects, which can provide effective information for clinical intervention and play an important role in guiding the development of CAR-T therapy.n